Related Experiment Video
Updated: Apr 12, 2026
Model of Ischemic Heart Disease and Video-Based Comparison of Cardiomyocyte Contraction Using hiPSC-Derived Cardiomyocytes
Published on: May 5, 2020
Importance and feasibility of creating hypertrophic cardiomyopathy centers in developing countries: the experience in
1Hypertrophic Cardiomyopathy Center, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.
Insights
Hypertrophic cardiomyopathy (HC), a common genetic heart disease, now has significantly reduced mortality with advanced treatments. A new dedicated center in India offers hope for improved HC management in developing nations.
Area of Science:
- Cardiology
- Genetics
- Public Health
Background:
- Hypertrophic cardiomyopathy (HC) is a prevalent genetic heart disease causing significant mortality and morbidity.
- Modern treatments like defibrillators and surgical myectomy have reduced HC-related mortality to 0.5% annually in developed nations.
- HC is a lower priority in developing countries due to the prevalence of other cardiac conditions like coronary artery disease and hypertension.
Discussion:
- Optimal management of HC is best achieved in specialized institutional centers.
- This model has been successfully implemented in the US, Canada, Europe, and Australia.
- A novel HC program has been established at Amrita Institute of Medical Sciences and Research in India.
Key Insights:
- The establishment of a dedicated HC center in India marks a significant advancement.
- This initiative was developed despite numerous challenges within the Indian healthcare system.
- The program aims to improve HC care and outcomes in a developing country context.
Outlook:
- This initiative represents a crucial step forward in addressing HC in India.
- The model's success could pave the way for similar centers in other developing nations.
- Further reporting will detail the program's structure and impact on HC patient care.
Abstract:
Hypertrophic cardiomyopathy (HC) is a relatively common genetic heart disease responsible for mortality and morbidity at all ages. Using contemporary treatment advances, such as implantable defibrillators, surgical myectomy, heart transplant, and modern defibrillation for out-of-hospital cardiac arrest, it is now possible to reduce HC-related mortality considerably to 0.5% per year, less than expected in the general US adult population. However, in much of the developing world, HC has not yet become a priority given the many other cardiac conditions, such as coronary artery disease and systemic hypertension, so prevalent in the most populous countries such as China and India. Management of HC is best achieved in dedicated centers within institutions, such as previously demonstrated in the United States, Canada, some European countries, and Australia. This model has recently been introduced for the first time in India at the Amrita Institute of Medical Sciences and Research in Kochi, Kerala, in which a robust program focused on HC has emerged. This novel initiative, created despite the many obstacles in the Indian health care system, is an important step forward and is reported here detail.
More Related Videos
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:29Cardiomyopathy V: Interprofessional Care
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:25Cardiomyopathy I: Introduction and Classification
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies